Five-Year Study Finds Significant Reduction of Occlusion and Infection With Use of PICCs

Article

NATICK, Mass. -- Boston Scientific Corporation announces the results of a five-year retrospective study on peripherally inserted central catheters (PICCs) with pressure activated safety valve (PASV) technology, indicating a significant reduction in rates of both occlusion (closure) and infection. The study, conducted by Vanderbilt University Medical Center (VUMC) in Nashville, Tenn., was presented at the Association for Vascular Access (AVA) Annual Conference in Savannah, Ga.

PICCs provide reliable access to the blood stream for patients requiring intravenous antibiotics, total parenteral nutrition, chemotherapy, blood products and blood sampling. The Vanderbilt study collected data over a five-year period on more than 12,500 PICC procedures performed by trained personnel in VUMCs specialized PICC nursing program.

This study provided us with compelling data that has shown significant benefits of the pressure-activated safety valve and a PICC team placement environment, says Doug Burns, RN, of Vanderbilt Medical Center, who presented the results at AVA. We are encouraged by the significant reduction in chances for occlusion and infections with the PASV Valve technology. The results should be welcome news to patients requiring intravenous treatments, as well as their physicians and infusion therapy clinicians.

The retrospective analysis revealed an increasing rate of successful placements since the inception of VUMCs PICC Service program in 2000.

Further, the choice of PICC technology had a significant impact on the likelihood for catheter occlusion and infection, both complications that can result from PICC procedures. Specifically, patient outcomes demonstrated statistically significant lower rates of occlusion, infection, or both when the PICCs with PASV Valve technology were used.  The chance for occlusion was 4.81 times lower, while infection was 1.35 times lower. Overall, the chance for either occlusion or infection was 2.24 times lower when patients received a PICC with PASV Valve technology.

This comprehensive study is another important step in establishing the clinical advantages of Boston Scientific's PASV Valve technology products, says Dave McClellan, president of Boston Scientifics Oncology business. The positive results should reinforce clinician confidence in using PASV Valve technology to deliver and maintain critical treatments to patients.

Boston Scientific offers a broad family of pressure activated safety valve products, including the Vaxcel PICC with PASV Valve technology. The U.S. PICC market is currently estimated at $130 million with an annual growth rate of approximately 20 percent.

Source: Boston Scientific Corporation

 

Recent Videos
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Concept images of Far-UVC  (Adobe Stock 316993517 by hopenv)
Related Content